Bio Solution said on Wednesday that it recently held a joint online academic lecture event with Heung-K Hospital, which included an observation of a CartiLife surgery, the company’s knee cartilage regeneration therapy.
Held in Heung-K Hospital's conference room, the event proceeded in the following order: the appointment of advisory board members, a plaque presentation ceremony, an online academic lecture, and an observation of cartilage implantation surgery. Heung-K Hospital Chief Director Kim Jong-keun and Bio Solution CEO Lee Jung-sun co-hosted the event.
Kim, appointed as an official consultant for Bio Solution, said he plans to actively participate in the clinical application and R&D process of next-generation cartilage regeneration therapies, including CartiLife, according to the company.
Kim also delivered an online lecture titled “CartiLife vs. Stem Cells: Why CartiLife Is Superior in Knee Cartilage Regeneration” from Heung-K Hospital's studio. During the lecture, Kim compared stem cell-based therapies and CartiLife based on clinical evidence and shared Heung-K Hospital's clinical experience and research achievements.
The lecture was followed by an observation event for cartilage implantation surgery performed by Kim. CEO Lee and other Bio Solution executives observed the clinical application process firsthand.
“Although stem cell therapy has anti-inflammatory and pain-relieving effects, its cartilage regenerative capacity is limited. The problem lies in insufficient cell numbers, differentiation capabilities, and the lack of standardized protocols,” Kim explained. “In contrast, CartiLife is a fourth-generation autologous chondrocyte therapy utilizing the patient's costal cartilage cells. It has no immune rejection response and enables long-term regeneration into tissue similar to native cartilage.”
CartiLife is a fourth-generation autologous chondrocyte implantation therapy (ACIT) developed by Bio Solution, a Kosdaq-listed biotech firm.
“CartiLife can become a new standard for knee cartilage regeneration, surpassing the limitations of stem cell therapy,” Kim said. “Heung-K Hospital will continue to provide cutting-edge treatments to patients domestically and internationally, establishing itself as a hub connecting research and clinical practice.”